P-225 XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis)/docetaxel (doc) outcome in stage III non-small-cell lung cancer (NSCLC): a genetic analysis of the Spanish Lung Cancer Group phase II trial 9901

Autor:	Jose Luis Ramirez, Carme Sarries, Rafael Rosell, Pilar Garrido, Jose Javier Sanchez, Laura Nun˜ez, Miquel Taron, Dolores Isla, Julio Astudillo, Barbara Roig
Rok vydání:	2003
Předmět:	Pulmonary and Respiratory Medicine Oncology Cisplatin Cancer Research medicine.medical_specialty business.industry medicine.disease Genetic analysis Gemcitabine Stage III Non-Small Cell Lung Cancer Docetaxel Internal medicine Medicine business Lung cancer Gene medicine.drug
Zdroj:	Lung Cancer. 41:S148
ISSN:	0169-5002
DOI:	10.1016/s0169-5002(03)92194-5
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2b17d20c182768af82f6170d6fb3e360 https://doi.org/10.1016/s0169-5002(03)92194-5 Zobrazit plný text záznamu Full Text from ScienceDirect